GT Biopharma, Inc. short interest in 2021
In 2021, GT Biopharma, Inc.'s disclosed short interest ran from 4.29% of shares outstanding on 15 Apr 2021 to 2.91% on 31 Dec 2021, a change of -1.38 percentage points. The year's high was 7.17% on 28 May 2021 and its low 2.69% on 29 Oct 2021, averaging 4.25% across 18 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.73 days on 15 Jul 2021. Full history: GT Biopharma, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 4.29% (15 Apr 2021)
- End of year
- 2.91% (31 Dec 2021)
- Change
- -1.38 pp
- High
- 7.17% (28 May 2021)
- Low
- 2.69% (29 Oct 2021)
- Average
- 4.25%
- Highest days to cover
- 7.73 (15 Jul 2021)
- SEC filings marked
- 4
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Apr 2021 | 4.29% | 1.10 | |
| 30 Apr 2021 | 4.93% | 3.28 | 10-K filed |
| 14 May 2021 | 5.28% | 2.06 | |
| 28 May 2021 | 7.17% | 5.84 | 10-Q filed |
| 15 Jun 2021 | 4.63% | 3.41 | |
| 30 Jun 2021 | 6.50% | 3.11 | |
| 15 Jul 2021 | 5.61% | 7.73 | |
| 30 Jul 2021 | 5.03% | 6.00 | |
| 13 Aug 2021 | 4.96% | 7.49 | |
| 31 Aug 2021 | 4.09% | 2.37 | 10-Q filed |
| 15 Sep 2021 | 3.89% | 4.03 | |
| 30 Sep 2021 | 3.08% | 2.43 | |
| 15 Oct 2021 | 2.77% | 3.13 | |
| 29 Oct 2021 | 2.69% | 3.95 | |
| 15 Nov 2021 | 2.73% | 1.79 | 10-Q filed |
| 30 Nov 2021 | 3.05% | 4.00 | |
| 15 Dec 2021 | 2.89% | 2.42 | |
| 31 Dec 2021 | 2.91% | 3.44 |
See also: GT Biopharma, Inc.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.